Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.78 |
| ▸ | PGGT1B | P53609 | 15/20 | 0.78 |
| ▸ | FNTB | P49356 | 14/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1396830 | 0.95 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL21933140 | 0.95 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL31561401 | 0.95 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL20564403 | 0.95 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL10018886 | 0.92 | FNTA (0.66) | FNTAPGGT1BFNTBTDP1 | |
| SCHEMBL16136628 | 0.89 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| SCHEMBL7608404 | 0.89 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| SCHEMBL6775184 | 0.89 | FNTA (0.69) | FNTAPGGT1BFNTB | |
| SCHEMBL6774841 | 0.89 | FNTA (0.73) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Hydrochloric Acid SCHEMBL6776199 | 0.88 | FNTA (0.70) | FNTAPGGT1BFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2010063910-A1 | USE OF GERANYL-GERANYL TRANSFERASE IN TREATING SPINAL CORD LESIONS | PHARMAXON (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2007118009-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | FNTA 161/4885PGGT1B 735/4885FNTB 106/4885 |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885FNTB 12/4885 |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885FNTB 12/4885 |
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885FNTB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.